AAMI 22442 3 2007 RA 2016
$93.55
ANSI/AAMI/ISO 22442-3:2007/(R)2016 – Medical devices utilizing animal tissues and their derivatives-Part 3: Validation of the elimination and/or inactivation of viruses and transimissible spongiform encephalopathy (TSE) agents
Published By | Publication Date | Number of Pages |
AAMI | 2007 | 36 |
Specifies requirements for the validation of the elimination and/or inactivation of viruses and TSE agents during the manufacture of medical devices (excluding in-vitro diagnostic medical devices) utilizing animal tissue or products derived from animal tissue, which are non-viable or have been rendered non-viable. Does not cover other transmissible and non-transmissible agents.
PDF Catalog
PDF Pages | PDF Title |
---|---|
1 | ANSI/AAMI/ISO 22442-3:2007/(R)2016, Medical devices utilizing animal tissues and their derivatives—Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents |
2 | Objectives and uses of AAMI standards andrecommended practices |
3 | Title Page |
4 | AAMI Standard Copyright information |
5 | Contents |
6 | Glossary of equivalent standards |
8 | Committee representation |
9 | Background of AAMI Adoption of ISO 22442-3:2007 |
11 | Foreword |
12 | Introduction |
13 | 1 Scope 2 Normative references |
14 | 3 Terms and definitions |
15 | 4 General requirements 4.1 Risk management 4.2 Sourcing and manufacturing process 4.3 General requirements related to validation 4.3.1 Documented procedures 4.3.2 Personnel |
16 | 4.3.3 Calibration 4.3.4 Equipment 4.3.5 Experimental systems 5 Literature review 5.1 Conduct of the literature review 5.2 Application of literature review output 5.3 Viruses |
17 | 5.4 TSE agents 6 Elimination and/or inactivation study of viruses and TSE agents 6.1 General 6.2 Protocol |
18 | 6.3 Conduct of the study 6.4 Interpretation of data 7 Final report |
19 | 8 Review of final report 9 Routine monitoring and control of critical process parameters |
20 | Annex A Requirements related to literature review A.1 General A.1.1 Methodology A.1.1.1 General A.1.1.2 Objective |
21 | A.1.1.3 Identification of data A.1.1.4 Relevance of data |
22 | A.1.1.5 Assessment A.1.2 Critical evaluation |
23 | A.2 Conclusions A.3 Report |
24 | Annex B Guidance on the elimination and/or inactivation study for viruses B.1 General B.2 Selection of viruses |
25 | B.3 Design and implications of elimination and/or inactivation studies B.3.1 General B.3.2 Design of the study |
26 | B.3.3 Culturing model viruses B.3.4 Conduct of cell culture tests B.3.5 Reduction factors |
27 | B.4 Elimination and/or inactivation study limitations |
29 | Annex C Guidance on the elimination and/or inactivation study for TSE agents C.1 General C.2 TSE agents surviving inactivation steps |
31 | Annex D Guidance on scaling down |
32 | Annex E Statistical evaluation of virus titres and reduction factors andassessment of their validity |
33 | Annex F Calculation of reduction factors |
34 | Annex G Probability of detection of agents at low concentrations |
35 | Bibliography |